Refine Search

Search Results -

Terms	Documents
gehant.in.	2

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L12

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Friday, September 03, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT; PLUR=YES; OP=OR		
L12	gehant.in.	2	L12
L11	l9 and L10	30	L11
L10	l8 and (MgSO4)	460	L10
L9	L8 and PEI	619	L9
L8	L7 and solubility enhancer	48676	L8
L7	L6 and expanded bed	182082	L7
L6	L5 and column chromatography	191286	L6
L5	L4 and centrifugation	56761	L5
L4	L3 and (pH 4)	322544	L4
L3	L2 and acidic pH	322548	L3
L2	L1 and E. coli	50942	L2
L1	protein extract$	517281	L1

END OF SEARCH HISTORY

h e b b cg b e e ch

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6213340 B1

L12: Entry 1 of 2 File: USPT Apr 10, 2001

US-PAT-NO: 6213340
DOCUMENT-IDENTIFIER: US 6213340 B1

TITLE: Ice bucket for bottles, especially a champagne bucket

DATE-ISSUED: April 10, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gehant; Andre Maurice Gilbert	Faucogney			FR

US-CL-CURRENT: 220/752; 220/770, 220/775

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 2. Document ID: US 4626204 A

L12: Entry 2 of 2 File: USPT Dec 2, 1986

US-PAT-NO: 4626204
DOCUMENT-IDENTIFIER: US 4626204 A

TITLE: High-temperature hot-air generator

DATE-ISSUED: December 2, 1986

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Saint Julian; Raymond M.	Couvrut			FR
Gehant; Philippe M.	Le Chesnay			FR
Bertrand; Ivan G.	Paris			FR
Folliet; Michel H.	Gargenville			FR

US-CL-CURRENT: 432/222; 110/265, 431/183, 431/186, 431/188, 431/190

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

h e b b g e e e f e b ef b e

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
gehant.in.	2

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e b ef b e

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 10 of 30 returned.

☐ 1. Document ID: US 6784151 B2

L11: Entry 1 of 30 File: USPT Aug 31, 2004

US-PAT-NO: 6784151
DOCUMENT-IDENTIFIER: US 6784151 B2

TITLE: Processes for making granular detergent composition having improved appearance and solubility

DATE-ISSUED: August 31, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Capeci; Scott William	North Bend	OH		
Gabriel; Steven Matthew	Cincinnati	OH		
Jagannath; Girish	Higashinada-ku			JP
Donoghue; Scott John	Jesmond			GB
Morrison; Christopher Andrew	Brussels			BE

US-CL-CURRENT: 510/444; 23/313FB, 264/117, 264/140, 510/438

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 2. Document ID: US 6777539 B2

L11: Entry 2 of 30 File: USPT Aug 17, 2004

US-PAT-NO: 6777539
DOCUMENT-IDENTIFIER: US 6777539 B2

TITLE: Soluble zalpha11 cytokine receptors

DATE-ISSUED: August 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sprecher; Cindy A.	Seattle	WA		
Novak; Julia E.	Bainbridge Island	WA		
West; James W.	Seattle	WA		
Presnell; Scott R.	Tacoma	WA		

h e b b g e e e f e b ef b e

Holly; Richard D.	Seattle	WA
Nelson; Andrew J.	Shoreline	WA

US-CL-CURRENT: 530/350; 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw De

---

☐ 3. Document ID: US 6770609 B1

L11: Entry 3 of 30 File: USPT Aug 3, 2004

US-PAT-NO: 6770609
DOCUMENT-IDENTIFIER: US 6770609 B1

TITLE: Light reflecting particles

DATE-ISSUED: August 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morrison; Christopher Andrew	Cullercoats			GB

US-CL-CURRENT: 510/348; 510/440, 510/446

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw De

---

☐ 4. Document ID: US 6743791 B2

L11: Entry 4 of 30 File: USPT Jun 1, 2004

US-PAT-NO: 6743791
DOCUMENT-IDENTIFIER: US 6743791 B2

TITLE: Heterocyclic inhibitors of ERK2 and uses thereof

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cao; Jingrong	Newton	MA		
Green; Jeremy	Burlington	MA		
Hale; Michael	Bedford	MA		
Maltais; Francois	Tewksbury	MA		
Straub; Judy	Cambridge	MA		
Tang; Qing	Cambridge	MA		
Aronov; Alex	Watertown	MA		

US-CL-CURRENT: 514/235.8; 514/266.22, 514/275, 544/122, 544/284, 544/331

h e b b g e e e f e b ef b e

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 5. Document ID: US 6723523 B2

L11: Entry 5 of 30 File: USPT Apr 20, 2004

US-PAT-NO: 6723523
DOCUMENT-IDENTIFIER: US 6723523 B2

TITLE: System and method for investigating the effect of chemical and other factors on cell movement

DATE-ISSUED: April 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lynes; Michael A.	Willington	CT		
Knecht; David A.	Storrs	CT		

US-CL-CURRENT: 435/7.21; 435/287.1, 435/288.4, 435/288.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 6. Document ID: US 6692924 B2

L11: Entry 6 of 30 File: USPT Feb 17, 2004

US-PAT-NO: 6692924
DOCUMENT-IDENTIFIER: US 6692924 B2

TITLE: Methods of using cytokine receptor zalpha11 to detect its ligands

DATE-ISSUED: February 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Presnell; Scott R.	Tacoma	WA		
Conklin; Darrell C.	Seattle	WA		
Novak; Julia E.	Bainbridge Island	WA		
Hammond; Angela K.	Issaquah	WA		

US-CL-CURRENT: 435/7.1; 435/69.7, 435/7.2, 530/350, 530/351

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 7. Document ID: US 6683043 B1

L11: Entry 7 of 30 File: USPT Jan 27, 2004

h e b b g e e e f e b ef b e

US-PAT-NO: 6683043
DOCUMENT-IDENTIFIER: US 6683043 B1

TITLE: Process for manufacturing effervescence components

DATE-ISSUED: January 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dovey; Anthony	Swarland			GB
Gray; Peter Gerard	Killingworth			GB
Baston; Gail Margaret	Whitley Bay			GB
Dyter; Zoe	Gosforth			GB
Driffield; Christopher Charles	High Heaton			GB
York; David William	Ponteland			GB

US-CL-CURRENT: 510/444; 510/446, 510/509, 510/513, 510/533

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw De

☐ 8. Document ID: US 6677147 B2

L11: Entry 8 of 30 File: USPT Jan 13, 2004

US-PAT-NO: 6677147
DOCUMENT-IDENTIFIER: US 6677147 B2

TITLE: Pectate lyases

DATE-ISSUED: January 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Andersen; Lene Nonboe	Allerod			DK
Schulein; Martin	late of Copenhagen			DK
Lange; Niels Erik Krebs	Raleigh	NC		
Bj.o slashed.rnvad; Mads Eskelund	Frederiksberg			DK
M.o slashed.ller; S.o slashed.ren	Holte			DK
Glad; Sanne O. Schroder	Ballerup			DK
Kauppinen; Markus Sakari	Copenhagen N			DK
Schnorr; Kirk	Copenhagen N			DK
Kongsbak; Lars	Holte			DK

US-CL-CURRENT: 435/232

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw De

☐ 9. Document ID: US 6635610 B1

h e b b g e e e f e b ef b e

L11: Entry 9 of 30 File: USPT Oct 21, 2003

US-PAT-NO: 6635610
DOCUMENT-IDENTIFIER: US 6635610 B1

TITLE: Detergent granules

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tatsuno; Teruaki	Osaka			JP
Hartshorn; Richard Timonthy	Wylam			GB
Norwood; Kevin	Cincinnati	OH		
Mort, III; Paul R.	Cincinnati	OH		
Bohlen; David Scott	West Chester	OH		
Gabriel; Steven Matthew	Cincinnati	OH		
Katsuda; Rinko	Kobe			JP
Hidalgo; Noe Ongcoy	Higashinada-Kobe			JP

US-CL-CURRENT: 510/276; 510/352, 510/438, 510/446, 510/498, 510/509

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw De

☐ 10. Document ID: US 6583098 B1

L11: Entry 10 of 30 File: USPT Jun 24, 2003

US-PAT-NO: 6583098
DOCUMENT-IDENTIFIER: US 6583098 B1

TITLE: Detergent composition

DATE-ISSUED: June 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cassie; Leslie Hugh	Morpeth			GB

US-CL-CURRENT: 510/376; 510/444

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L9 and L10	30

h e b b g e e e f e b ef b e

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#

h e b b g e e e f e b ef b e

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	May 12	EXTEND option available in structure searching
NEWS 4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS 6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS 7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS 8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS 9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS 10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS 11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS 12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS 13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS 14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS 15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS 16	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 17	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS 18	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS 19	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS 20	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX

NEWS EXPRESS	JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004

=> file medline, uspatful, dgene, embase, wpids, fsta
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 09:40:33 ON 03 SEP 2004

FILE 'USPATFULL' ENTERED AT 09:40:33 ON 03 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 09:40:33 ON 03 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 09:40:33 ON 03 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 09:40:33 ON 03 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 09:40:33 ON 03 SEP 2004
COPYRIGHT (C) 2004 International Food Information Service

=> s protein extract?
L1 14397 PROTEIN EXTRACT?

=> s l1 and E. coli cells
5 FILES SEARCHED...
L2 1187 L1 AND E. COLI CELLS

=> s protein extraction with acidic pH
L3 0 PROTEIN EXTRACTION WITH ACIDIC PH

=> s l2 and acid
L4 1172 L2 AND ACID

=> s l2 and acidic pH
L5 28 L2 AND ACIDIC PH

=> s l5 and l4
L6 28 L5 AND L4

=> s l6 and disrupt cells
L7 0 L6 AND DISRUPT CELLS

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 28 USPATFULL on STN
TI Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:184572 USPATFULL
TITLE: Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004142455	A1	20040722
APPLICATION INFO.:	US 2003-729039	A1	20031205 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Page(s)
LINE COUNT: 9089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 28 USPATFULL on STN
TI Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:150994 USPATFULL
TITLE: Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004115215	A1	20040617
APPLICATION INFO.:	US 2003-729122	A1	20031205 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Page(s)
LINE COUNT: 16342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 28 USPATFULL on STN
TI Process for **protein extraction**
AB The invention includes a process for extracting a target protein from **E. coli cells** that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:64493 USPATFULL
TITLE: Process for **protein extraction**
INVENTOR(S): Gehant, Richard L., South San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004049012	A1	20040311	
APPLICATION INFO.:	US 2003-655874	A1	20030905	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-408653P	20020906 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 28 USPATFULL on STN
TI Transmembrane proteins
AB The invention provides human transmembrane proteins (TMP) and polynucleotides which identify and encode TMP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of TMP.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:64491 USPATFULL
TITLE: Transmembrane proteins
INVENTOR(S): Warren, Bridget A, Encinitas, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Batra, Sajeev, Oakland, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Duggan, Brendan M, Sunnyvale, CA, UNITED STATES

Baughn, Mariah R, San Leandro, CA, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Khan, Farrah A, Glen View, IL, UNITED STATES
Nguyen, Danniel B, San Jose, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Yao, Monique G, Carmel, IN, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Thangavelu, Kavitha, Mountain View, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Tran, Bao, Santa Clara, CA, UNITED STATES
Ding, Li, Creve Coeur, MI, UNITED STATES
Au-Young, Janice K, Brisbane, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004049010	A1	20040311	
APPLICATION INFO.:	US 2003-415188	A1	20030423	(10)
	WO 2001-US49670		20011026	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INCYTE CORPORATION (formerly known as Incyte, Genomics, Inc.), 3160 PORTER DRIVE, PALO ALTO, CA, 94304
NUMBER OF CLAIMS: 89
EXEMPLARY CLAIM: 1
LINE COUNT: 7985
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 28 USPATFULL on STN
TI Soluble recombinant botulinum toxins
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:311862 USPATFULL
TITLE: Soluble recombinant botulinum toxins
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA, UNITED STATES, 92612 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003219457	A1	20031127	
APPLICATION INFO.:	US 2002-271012	A1	20021015	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Page(s)
LINE COUNT: 16361
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 28 USPATFULL on STN
TI Soluble recombinant botulinum toxin proteins
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:306036 USPATFULL		
TITLE:	Soluble recombinant botulinum toxin proteins		
INVENTOR(S):	Williams, James A., Madison, WI, UNITED STATES Thalley, Bruce S., Madison, WI, UNITED STATES		
PATENT ASSIGNEE(S):	Allergan, Inc., Allergan Botox Limited, Irvine, CA, 92612 (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215468	A1	20031120
APPLICATION INFO.:	US 2003-354774	A1	20030130 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Page(s)		
LINE COUNT:	16347		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 28 USPATFULL on STN
TI Methods and reagents for decreasing clinical reaction to allergy
AB It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino **acid** within the protein, preferably a hydrophobic residue towards the center of the IgE epitope, to eliminate IgE binding. Additionally or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemically, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino **acid** sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE eitopes and disrupting one or more disulfide bonds of the natural allergen. In certain embodiments, the methods of the present invention allow allergens to be modified while retaining the ability of the protein to activate T-cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The Examples provided herein use peanut allergens to illustrate applications of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:288222 USPATFULL
TITLE:	Methods and reagents for decreasing clinical reaction

to allergy

INVENTOR(S): Caplan, Michael J., Woodbridge, CT, UNITED STATES
Sosin, Howard B., Fairfield, CT, UNITED STATES
Sampson, Hugh, Larchmont, NY, UNITED STATES
Bannon, Gary A., Wentzville, MO, UNITED STATES
Burks, A. Wesley, JR., Little Rock, AR, UNITED STATES
Cockrell, Gael, Cabot, AR, UNITED STATES
Compadre, Cesar M., Little Rock, AR, UNITED STATES
Connaughton, Cathie, Conway, AR, UNITED STATES
Helm, Ricki M., Little Rock, AR, UNITED STATES
King, Nina E., Mason, OH, UNITED STATES
Kopper, Randall A., Conway, AR, UNITED STATES
Maleki, Soheila J., New Orleans, LA, UNITED STATES
Rabjohn, Patrick A., Little Rock, AR, UNITED STATES
Shin, David S., San Diego, CA, UNITED STATES
Stanley, J. Steven, North Little Rock, AR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003202980	A1	20031030
APPLICATION INFO.:	US 2002-100303	A1	20020318 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-494096, filed on 28 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-267719, filed on 11 Mar 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-248674, filed on 11 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-248673, filed on 11 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-241101, filed on 29 Jan 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-240557, filed on 29 Jan 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-141220, filed on 27 Aug 1998, PENDING Continuation-in-part of Ser. No. US 1998-106872, filed on 29 Jun 1998, GRANTED, Pat. No. US 6486311 Continuation-in-part of Ser. No. US 1998-191593, filed on 13 Nov 1998, PENDING Continuation of Ser. No. US 1996-717933, filed on 23 Sep 1996, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-122450P	19990302 (60)
	US 1999-122452P	19990302 (60)
	US 1999-122560P	19990302 (60)
	US 1999-122565P	19990302 (60)
	US 1999-122566P	19990302 (60)
	US 1998-74633P	19980213 (60)
	US 1998-74624P	19980213 (60)
	US 1998-74590P	19980213 (60)
	US 1998-73283P	19980131 (60)
	US 1995-9455P	19951229 (60)
	US 2001-276822P	20010316 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 99 Drawing Page(s)
LINE COUNT: 6600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 28 USPATFULL on STN
TI Method for cleavage of fusion proteins

AB An improved method for recovering recombinantly produced polypeptides is described. The method involves expressing the recombinant polypeptide as a fusion protein with a pro-peptide. The pro-peptide-polypeptide fusion protein can be cleaved and the recombinant polypeptide released under the appropriate conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:238005 USPATFULL
TITLE:	Method for cleavage of fusion proteins
INVENTOR(S):	Van Rooijen, Gijs, Calgary, CANADA Alcantara, Joenel, Calgary, CANADA Moloney, Maurice M., Calgary, CANADA
PATENT ASSIGNEE(S):	SemBioSys Genetics Inc., Calgary, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166162	A1	20030904
APPLICATION INFO.:	US 2002-322746	A1	20021219 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-402488, filed on 16 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-CA398, filed on 23 Apr 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-44254P	19970425 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	BERESKIN AND PARR, SCOTIA PLAZA, 40 KING STREET WEST-SUITE 4000 BOX 401, TORONTO, ON, M5H 3Y2
NUMBER OF CLAIMS:	53
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	19 Drawing Page(s)
LINE COUNT:	1991

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 28 USPATFULL on STN

TI Methods and compositions for production of recombinant peptides

AB This invention entails a method for solubilizing and recovering, in bioactive and isolated form with retained native state configuration, a target peptide from a host organism in which the heterologous polypeptide is present in insoluble form. Broadly this method comprises (i) disrupting the host cell to produce a lysate (ii) recovering lysate precipitate containing the polypeptide (iii) resuspending the lysate precipitate in a denaturant-free, non-buffered solubilization solution to produce a solubilization preparation that comprises both sodium hydroxide between about 8 and about 10 mM and the target peptide between about 1 and about 4 mg peptide per ml solubilization solution, wherein the resultant solubilization preparation has a pH of between about 9 and about 11.2; (iv) recovering supernatant from the solubilization preparation containing non-denatured target peptide. Optionally, stabilizing compounds and detergents are employed. The invention further comprises isolated insoluble proteins in bioactive form and native state configuration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:237905 USPATFULL
TITLE:	Methods and compositions for production of recombinant peptides
INVENTOR(S):	Gonzalez-Villasenor, Lucia Irene, Baltimore, MD, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2003166062	A1	20030904
APPLICATION INFO.:	US 2002-80919	A1	20020222 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-270839P	20010223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Thomas M Saunders, Brown Rudnick Berlack Israels LLP, 18th Floor, One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2054
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 28 USPATFULL on STN

TI Vaccine and antitoxin for treatment and prevention of C. difficile disease

AB The present provides neutralizing antitoxin directed against C. difficile toxins. These antitoxins are produced in avian species using soluble recombinant C. difficile toxin proteins. The avian antitoxins are designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:234579 USPATFULL
TITLE: Vaccine and antitoxin for treatment and prevention of C. difficile disease
INVENTOR(S): Kink, John A., Madison, WI, United States
Williams, James A., Lincoln, NE, United States
PATENT ASSIGNEE(S): Promega Corporation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6613329	B1	20030902
APPLICATION INFO.:	US 1998-84517		19980526 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-422711, filed on 14 Apr 1995, now abandoned Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, now patented, Pat. No. US 5919665 Continuation-in-part of Ser. No. US 1994-329154, filed on 24 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 Continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 Continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary
ASSISTANT EXAMINER: Turner, Sharon
LEGAL REPRESENTATIVE: Medlen & Carroll, LLP
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 46 Drawing Page(s)

LINE COUNT: 11913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 28 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic **acid** molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:134527 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092615	A1	20030515
APPLICATION INFO.:	US 2002-115928	A1	20020405 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764861, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)
	US 2000-236369P	20000929 (60)
	US 2000-224519P	20000814 (60)
	US 2000-220964P	20000726 (60)
	US 2000-241809P	20001020 (60)
	US 2000-249299P	20001117 (60)
	US 2000-236327P	20000929 (60)

US 2000-241785P 20001020 (60)
US 2000-244617P 20001101 (60)
US 2000-225268P 20000814 (60)
US 2000-236368P 20000929 (60)
US 2000-251856P 20001208 (60)
US 2000-251868P 20001208 (60)
US 2000-229344P 20000901 (60)
US 2000-234997P 20000925 (60)
US 2000-229343P 20000901 (60)
US 2000-229345P 20000901 (60)
US 2000-229287P 20000901 (60)
US 2000-229513P 20000905 (60)
US 2000-231413P 20000908 (60)
US 2000-229509P 20000905 (60)
US 2000-236367P 20000929 (60)
US 2000-237039P 20001002 (60)
US 2000-237038P 20001002 (60)
US 2000-236370P 20000929 (60)
US 2000-236802P 20001002 (60)
US 2000-237037P 20001002 (60)
US 2000-237040P 20001002 (60)
US 2000-240960P 20001020 (60)
US 2000-239935P 20001013 (60)
US 2000-239937P 20001013 (60)
US 2000-241787P 20001020 (60)
US 2000-246474P 20001108 (60)
US 2000-246532P 20001108 (60)
US 2000-249216P 20001117 (60)
US 2000-249210P 20001117 (60)
US 2000-226681P 20000822 (60)
US 2000-225759P 20000814 (60)
US 2000-225213P 20000814 (60)
US 2000-227182P 20000822 (60)
US 2000-225214P 20000814 (60)
US 2000-235836P 20000927 (60)
US 2000-230438P 20000906 (60)
US 2000-215135P 20000630 (60)
US 2000-225266P 20000814 (60)
US 2000-249218P 20001117 (60)
US 2000-249208P 20001117 (60)
US 2000-249213P 20001117 (60)
US 2000-249212P 20001117 (60)
US 2000-249207P 20001117 (60)
US 2000-249245P 20001117 (60)
US 2000-249244P 20001117 (60)
US 2000-249217P 20001117 (60)
US 2000-249211P 20001117 (60)
US 2000-249215P 20001117 (60)
US 2000-249264P 20001117 (60)
US 2000-249214P 20001117 (60)
US 2000-249297P 20001117 (60)
US 2000-232400P 20000914 (60)
US 2000-231242P 20000908 (60)
US 2000-232081P 20000908 (60)
US 2000-232080P 20000908 (60)
US 2000-231414P 20000908 (60)
US 2000-231244P 20000908 (60)
US 2000-233064P 20000914 (60)
US 2000-233063P 20000914 (60)
US 2000-232397P 20000914 (60)
US 2000-232399P 20000914 (60)
US 2000-232401P 20000914 (60)
US 2000-241808P 20001020 (60)
US 2000-241826P 20001020 (60)

	US 2000-241786P	20001020 (60)
	US 2000-241221P	20001020 (60)
	US 2000-246475P	20001108 (60)
	US 2000-231243P	20000908 (60)
	US 2000-233065P	20000914 (60)
	US 2000-232398P	20000914 (60)
	US 2000-234998P	20000925 (60)
	US 2000-246477P	20001108 (60)
	US 2000-246528P	20001108 (60)
	US 2000-246525P	20001108 (60)
	US 2000-246476P	20001108 (60)
	US 2000-246526P	20001108 (60)
	US 2000-249209P	20001117 (60)
	US 2000-246527P	20001108 (60)
	US 2000-246523P	20001108 (60)
	US 2000-246524P	20001108 (60)
	US 2000-246478P	20001108 (60)
	US 2000-246609P	20001108 (60)
	US 2000-246613P	20001108 (60)
	US 2000-249300P	20001117 (60)
	US 2000-249265P	20001117 (60)
	US 2000-246610P	20001108 (60)
	US 2000-246611P	20001108 (60)
	US 2000-230437P	20000906 (60)
	US 2000-251990P	20001208 (60)
	US 2000-251988P	20001205 (60)
	US 2000-251030P	20001205 (60)
	US 2000-251479P	20001206 (60)
	US 2000-256719P	20001205 (60)
	US 2000-250160P	20001201 (60)
	US 2000-251989P	20001208 (60)
	US 2000-250391P	20001201 (60)
	US 2000-254097P	20001211 (60)
	US 2000-231968P	20000912 (60)
	US 2000-226279P	20000818 (60)
	US 2000-186350P	20000302 (60)
	US 2000-184664P	20000224 (60)
	US 2000-189874P	20000316 (60)
	US 2000-198123P	20000418 (60)
	US 2000-227009P	20000823 (60)
	US 2000-235484P	20000926 (60)
	US 2000-190076P	20000317 (60)
	US 2000-209467P	20000607 (60)
	US 2000-205515P	20000519 (60)
	US 2001-259678P	20010105 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 21689
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 28 USPATFULL on STN
TI Hyaluronan synthase genes and expression thereof in bacillus hosts
AB The present invention relates to a recombinant Bacillus host cell containing a recombinant vector including a nucleic **acid** segment having a coding region segment encoding enzymatically active hyaluronan synthase (HAS). The recombinant Bacillus host cell is utilized in a method for producing hyaluronic **acid** (HA).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:134033 USPATFULL

TITLE: Hyaluronan synthase genes and expression thereof in bacillus hosts

INVENTOR(S): DeAngelis, Paul L., Edmond, OK, UNITED STATES
Weigel, Paul H., Edmond, OK, UNITED STATES
Kumari, Kshama, Edmond, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092118	A1	20030515
APPLICATION INFO.:	US 2002-172527	A1	20020613 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-469200, filed on 21 Dec 1999, PENDING Continuation of Ser. No. US 1998-178851, filed on 26 Oct 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64435P	19971031 (60)
	US 2001-297788P	20010613 (60)
	US 2001-297744P	20010613 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DUNLAP, CODDING & ROGERS P.C., PO BOX 16370, OKLAHOMA CITY, OK, 73114
NUMBER OF CLAIMS: 308
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 4894
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 28 USPATFULL on STN
TI Hyaluronan synthase gene and uses thereof
AB The present invention relates to a nucleic **acid** segment having a coding region segment encoding enzymatically active Streptococcus equisimilis hyaluronate synthase (seHAS), and to the use of this nucleic **acid** segment in the preparation of recombinant cells which produce hyaluronate synthase and its hyaluronic **acid** product. Hyaluronate is also known as hyaluronic **acid** or hyaluronan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:120299 USPATFULL
TITLE: Hyaluronan synthase gene and uses thereof
INVENTOR(S): Weigel, Paul H., Edmond, OK, UNITED STATES
Kumari, Kshama, Oklahoma City, OK, UNITED STATES
DeAngelis, Paul, Edmond, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003082780	A1	20030501
APPLICATION INFO.:	US 2001-11771	A1	20011211 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-469200, filed on 21 Dec 1999, PENDING Continuation of Ser. No. US 1998-178851, filed on 26 Oct 1998, ABANDONED
Continuation-in-part of Ser. No. US 1998-146893, filed on 3 Sep 1998, GRANTED, Pat. No. US 6455304
Continuation of Ser. No. US 1994-270581, filed on 1 Jul 1994, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64435P	19971031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DUNLAP, CODDING & ROGERS P.C., PO BOX 16370, OKLAHOMA CITY, OK, 73114

NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 2904
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 28 USPATFULL on STN
TI Hyaluronan synthase gene and uses thereof
AB The present invention relates to a nucleic **acid** segment having a coding region segment encoding enzymatically active Streptococcus equisimilis hyaluronate synthase (seHAS), and to the use of this nucleic **acid** segment in the preparation of recombinant cells which produce hyaluronate synthase and its hyaluronic **acid** product. Hyaluronate is also known as hyaluronic **acid** or hyaluronan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:106310 USPATFULL
TITLE: Hyaluronan synthase gene and uses thereof
INVENTOR(S): Weigel, Paul H., Edmond, OK, UNITED STATES
Kumari, Kshama, Oklahoma City, OK, UNITED STATES
DeAngelis, Paul, Edmond, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073221	A1	20030417
APPLICATION INFO.:	US 2001-11768	A1	20011211 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-469200, filed on 21 Dec 1999, PENDING Continuation of Ser. No. US 1998-178851, filed on 26 Oct 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64435P	19971031 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DUNLAP, CODDING & ROGERS P.C., PO BOX 16370, OKLAHOMA CITY, OK, 73114
NUMBER OF CLAIMS: 59
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 2909
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 28 USPATFULL on STN
TI Apoptosis related polynucleotides, polypeptides, and antibodies
AB The present invention relates to novel human apoptosis related polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human apoptosis related polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human apoptosis related polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:71447 USPATFULL
TITLE: Apoptosis related polynucleotides, polypeptides, and antibodies
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2003049732	A1	20030313
APPLICATION INFO.:	US 2001-13477	A1	20011213 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-669445, filed on 25 Sep 2000, PENDING Continuation-in-part of Ser. No. WO 2000-US6642, filed on 15 Mar 2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-126018P	19990324 (60)
	US 1999-139638P	19990617 (60)
	US 1999-149449P	19990818 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 12594
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 28 USPATFULL on STN
TI Compositions and methods for treatment of neoplastic disease
AB The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides, nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compositions are tumor cells, hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are tumoricidal T cells and NKT cells devoid of inhitory receptors or inhibitory signaling motifs which are hyperresponsive to the the above compositions and lipid-based tumor associated antigens that can be administered for adoptive immunotherapy of cancer and infectious diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:315069 USPATFULL
TITLE: Compositions and methods for treatment of neoplastic disease
INVENTOR(S): Terman, David S., Pebble Beach, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002177551	A1	20021128
APPLICATION INFO.:	US 2001-870759	A1	20010530 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208128P	20000531 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: David S. Terman, P.O. Box 987, Pebble Beach, CA, 93953
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 17323
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 28 USPATFULL on STN

TI Streptococcus equisimilis hyaluronan synthase gene and expression thereof in Bacillus subtilis

AB The present invention relates to a nucleic **acid** segment having a coding region segment encoding enzymatically active Streptococcus equisimilis hyaluronate synthase (seHAS), and to the use of this nucleic **acid** segment in the preparation of recombinant cells which produce hyaluronate synthase and its hyaluronic **acid** product. Hyaluronate is also known as hyaluronic **acid** or hyaluronan.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:287626 USPATFULL
TITLE:	Streptococcus equisimilis hyaluronan synthase gene and expression thereof in Bacillus subtilis
INVENTOR(S):	Weigel, Paul H., Edmond, OK, UNITED STATES Kumari, Kshama, Oklahoma City, OK, UNITED STATES DeAngelis, Paul, Edmond, OK, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160489	A1	20021031
APPLICATION INFO.:	US 2001-879959	A1	20010912 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-469200, filed on 21 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1997-899040, filed on 23 Jul 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-64435P	19971031 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Dunlap, Codding & Rogers, P.C., Suite 420, 9400 North Broadway, Oklahoma City, OK, 73114
NUMBER OF CLAIMS:	59
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	14 Drawing Page(s)
LINE COUNT:	2727

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 28 USPATFULL on STN

TI Endonuclease compositions and methods of use

AB Disclosed are methods for modulating apoptosis and altering programmed cell death events using novel Endo-SR gene compositions and the polypeptides encoded thereby. Also disclosed are methods for repairing DNA, modulating genetic recombination in a cell, and altering DNA rearrangement in a host cell. Also disclosed are methods for the design and isolation of peptidomimetics and other inhibitors of Endo-SR useful in the treatment of leukemias, lymphomas, and other cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:246537 USPATFULL
TITLE:	Endonuclease compositions and methods of use
INVENTOR(S):	Aguilera, Renato J., Culver City, CA, United States Lyon, Christopher J., Los Angeles, CA, United States
PATENT ASSIGNEE(S):	The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6455250	B1	20020924
APPLICATION INFO.:	US 1998-210422		19981211 (9)

	NUMBER	DATE

PRIORITY INFORMATION: US 1997-69205P 19971211 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Priebe, Scott D.
ASSISTANT EXAMINER: Chen, Shin-Lin
LEGAL REPRESENTATIVE: Mandel & Adriano
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 6414
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 28 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic **acid** molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:165182 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002086811	A1	20020704	
	US 2003171252	A9	20030911	
APPLICATION INFO.:	US 2001-764861	A1	20010117	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)
	US 2000-228924P	20000830 (60)
	US 2000-224518P	20000814 (60)

US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 22023
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 28 USPATFULL on STN
TI Vaccine and antitoxin for the treatment of C. difficile disease
AB The present investion provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are produced with portions of C. difficile Toxin A, or Toxin B, or both. These portions of Toxins A and B may be fusion proteins with at least one non-toxin protein sequence, and may also be soluble and substantially endotoxin-free. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:157798 USPATFULL
TITLE: Vaccine and antitoxin for the treatment of C. difficile disease
INVENTOR(S): Kink, John A., Madison, WI, United States
Thalley, Bruce S., Madison, WI, United States
Stafford, Douglas C., Madison, WI, United States
PATENT ASSIGNEE(S): Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6290960	B1	20010918
APPLICATION INFO.:	US 1997-915136		19970820 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-480604, filed on 7 Jun

1995, now patented, Pat. No. US 5736139 Continuation-in-part of Ser. No. US 1995-422711, filed on 14 Apr 1995, now abandoned Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, now patented, Pat. No. US 5919665 Continuation-in-part of Ser. No. US 1994-329154, filed on 24 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 Continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 Continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Navarro, Albert
LEGAL REPRESENTATIVE: Medlen & Carroll, LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 55 Drawing Figure(s); 54 Drawing Page(s)
LINE COUNT: 11041
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 28 USPATFULL on STN

TI Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells

AB Disclosed are methods and compositions for producing heterologous disulfide bond containing polypeptides in bacterial cells. In preferred embodiments the methods involve co-expression of a prokaryotic disulfide isomerase, such as DsbC or DsbG and a gene encoding a recombinant eukaryotic polypeptide. Exemplary polypeptides disclosed include tissue plasminogen activator.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2000:84056 USPATFULL
TITLE: Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
INVENTOR(S): Georgiou, George, Austin, TX, United States
Oiu, Ji, Austin, TX, United States
Bessette, Paul, Austin, TX, United States
Swartz, James, Menlo Park, CA, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6083715		20000704	
APPLICATION INFO.:	US 1997-871483		19970609	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Patterson, Jr., Charles L.
ASSISTANT EXAMINER: Tung, Peter P.
LEGAL REPRESENTATIVE: Arnold, White & Durkee
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 2
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 28 USPATFULL on STN

TI Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells

AB Disclosed are methods of producing eukaryotic disulfide bond-containing

polypeptides in bacterial hosts, and compositions resulting therefrom. Co-expression of a eukaryotic foldase and a disulfide bond-containing polypeptide in a bacterial host cell is demonstrated. In particular embodiments, the methods have been used to produce mammalian pancreatic trypsin inhibitor and tissue plasminogen activator (tPA) in soluble, biologically-active forms, which are isolatable from the bacterial periplasm. Also disclosed are expression systems, recombinant vectors, and transformed host cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:21382 USPATFULL
TITLE:	Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells
INVENTOR(S):	Georgiou, George, Austin, TX, United States Ostermeier, Marc, State College, PA, United States
PATENT ASSIGNEE(S):	Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6027888		20000222	
APPLICATION INFO.:	US 1997-834516		19970404	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-14950P	19960405 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Guzo, David
ASSISTANT EXAMINER:	Sandals, William
LEGAL REPRESENTATIVE:	Arnold, White & Durkee
NUMBER OF CLAIMS:	40
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT:	4029

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 28 USPATFULL on STN

TI MN gene and protein

AB Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. The MN protein has been determined to be the first tumor-associated carbonic anhydrase isoenzyme that has been described. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression, e.g., immunoassays and nucleic **acid** hybridization assays, are provided. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, conjugated or unconjugated to cytotoxic agents, and the use of MN antisense nucleic acids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:21381 USPATFULL
TITLE:	MN gene and protein
INVENTOR(S):	Zavada, Jan, Prague, Czech Republic Pastorekova, Silvia, Bratislava, Slovakia Pastorek, Jaromir, Bratislava, Slovakia
PATENT ASSIGNEE(S):	Institute of Virology, Solvak Academy of Sciences, Bratislava, Slovakia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6027887		20000222

APPLICATION INFO.: US 1997-787739 19970124 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-485049, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-486756, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-477504, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-481658, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-485862, filed on 7 Jun 1995 Ser. No. Ser. No. US 1995-485863, filed on 7 Jun 1995 And Ser. No. US 1995-487077, filed on 7 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-260190, filed on 15 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-177093, filed on 30 Dec 1993 which is a continuation-in-part of Ser. No. US 1992-964589, filed on 21 Oct 1992, now patented, Pat. No. US 5387676, issued on 7 Feb 1995
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, W. Gary
ASSISTANT EXAMINER: Whisenant, Ethan
LEGAL REPRESENTATIVE: Lauder, Leona L., Morgenstern, Arthur S.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 5256
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 28 USPATFULL on STN
TI Vaccine for clostridium botulinum neurotoxin
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:75522 USPATFULL
TITLE: Vaccine for clostridium botulinum neurotoxin
INVENTOR(S): Williams, James A., Madison, WI, United States
PATENT ASSIGNEE(S): Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5919665		19990706
APPLICATION INFO.:	US 1995-405496		19950316 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-329154, filed on 25 Oct 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 which is a continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 which is a continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193, issued on 23 Mar 1993
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eisenschenk, Frank C.
ASSISTANT EXAMINER: Rabin, Evelyn
LEGAL REPRESENTATIVE: Medlen & Carroll, LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Figure(s); 29 Drawing Page(s)

LINE COUNT: 9164
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 28 USPATFULL on STN
TI Therapeutic fragments of von Willebrand factor
AB Processes for preparing aqueous solutions of cysteine-altered von Willebrand Factor fragment which are substantially free of aggregate and capable of therapeutic use for treating thrombosis are provided. The claimed process comprises providing an aqueous solution of vWF fragment and denaturant and containing undesired contaminants, said solution having an **acidic pH**; separating said contaminants from said solution by contacting said solution with an affinity chromatography medium to which said vWF fragments adhere; eluting said vWF fragment from said affinity chromatography medium in the presence of the denaturant; and separating the eluted fragment from said denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said fragment, thereby forming an aqueous solution of vWF fragment which is substantially free of aggregate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:154386 USPATFULL
TITLE: Therapeutic fragments of von Willebrand factor
INVENTOR(S): Farb, David L., Chalfont, PA, United States
Hrinda, Michael E., Gwynedd Valley, PA, United States
Lee, Ted C. K., Lansdale, PA, United States
Prior, Christopher P., Wayne, PA, United States
Weber, David, Norristown, PA, United States
PATENT ASSIGNEE(S): Centeon L.L.C., King of Prussia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5847086		19981208
APPLICATION INFO.:	US 1995-487445		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-198849, filed on 18 Feb 1994, now patented, Pat. No. US 5539086 which is a continuation of Ser. No. US 1991-717942, filed on 20 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Longton, Enrique D.
LEGAL REPRESENTATIVE: Synnestvedt & Lechner
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1680
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 28 USPATFULL on STN
TI Treatment of Clostridium difficile induced disease
AB The present provides neutralizing antitoxin directed against C. difficile toxins. These antitoxins are produced in arian species using soluble recombinant C. difficile toxin proteins. The avian antitoxins are designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:36359 USPATFULL
TITLE:	Treatment of Clostridium difficile induced disease
INVENTOR(S):	Kink, John A., Madison, WI, United States Thalley, Bruce S., Madison, WI, United States Stafford, Douglas C., Madison, WI, United States Firca, Joseph R., Vernon Hills, IL, United States Padhye, Nisha V., Madison, WI, United States
PATENT ASSIGNEE(S):	Ochidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5736139		19980407
APPLICATION INFO.:	US 1995-480604		19950607 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-422711, filed on 14 Apr 1995 which is a continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995 which is a continuation-in-part of Ser. No. US 1994-329154, filed on 24 Oct 1994 which is a continuation-in-part of Ser. No. US 1993-161907, filed on 2 Dec 1993, now patented, Pat. No. US 5601823 which is a continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 which is a continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193, issued on 23 Mar 1993

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Eisenschenk, Frank C.
LEGAL REPRESENTATIVE:	Medlen & Carroll, LLP
NUMBER OF CLAIMS:	28
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	55 Drawing Figure(s); 53 Drawing Page(s)
LINE COUNT:	11770

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 28 USPATFULL on STN

TI Recombinant mycobacterial seryl-tRNA synthetase genes, tester strains and assays

AB Isolated and/or recombinant nucleic acids encoding mycobacterial seryl-tRNA synthetase have been characterized. Recombinant DNA constructs and vectors having a sequence which encodes mycobacterial seryl-tRNA synthetase have been made, and can be used for the construction of tester strains as well as for the production of isolated and/or recombinant seryl-tRNA synthetases. These enzymes or portions thereof are useful in the biochemical separation of serine and quantification of serine or ATP, and for producing antibodies useful in the purification and study of the enzyme, for example. Host cells and methods useful for producing recombinant mycobacterial seryl-tRNA synthetases are described, as are tester strains, which are cells engineered to rely on the function of the tRNA synthetase encoded by an introduced cloned gene. Tester strains can be used to identify inhibitors of the essential tRNA synthetase enzyme encoded by the introduced cloned gene, and thus provide a means to assess the antimicrobial effect and specificity of the inhibitor without employing slow-growing, pathogenic strains of mycobacteria, such as Mycobacterium tuberculosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:70912 USPATFULL
TITLE:	Recombinant mycobacterial seryl-tRNA synthetase genes, tester strains and assays
INVENTOR(S):	Martinis, Susan A., Newton, MA, United States

	Zhang, Jiansu, Cambridge, MA, United States
	Schimmel, Paul R., Cambridge, MA, United States
PATENT ASSIGNEE(S):	Cubist Pharmaceuticals, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5656470		19970812
APPLICATION INFO.:	US 1994-305172		19940913 (8)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Wax, Robert A.
ASSISTANT EXAMINER:	Hobbs, Lisa J.
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds, P.C.
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
LINE COUNT:	2043

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 28 USPATFULL on STN

TI Therapeutic fragments of von Willebrand factor

AB An aqueous solution of cysteine-altered von Willebrand Factor fragment which is substantially free of aggregate and capable of therapeutic use for treating thrombosis and a process for preparing such a solution comprising:

(A) providing an aqueous solution of the fragment and denaturant;

(B) purifying the solution of fragment and denaturant under conditions which promote conversion of aggregated forms of the fragment to the dimeric and/or monomeric forms thereof to provide purified fragment;

(C) separating the dissolved, purified fragment from the denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said purified fragment, thereby forming an aqueous solution of fragment which is substantially free of aggregate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	96:65675 USPATFULL
TITLE:	Therapeutic fragments of von Willebrand factor
INVENTOR(S):	Farb, David L., Chalfont, PA, United States
	Hrinda, Michael E., Gwynedd Valley, PA, United States
	Lee, Ted C. K., Lansdale, PA, United States
	Prior, Christopher P., Wayne, PA, United States
PATENT ASSIGNEE(S):	Rh one-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5539086		19960723
APPLICATION INFO.:	US 1994-198849		19940218 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-717942, filed on 20 Jun 1991, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Jacobson, Dian C.
LEGAL REPRESENTATIVE:	Synnestvedt & Lechner
NUMBER OF CLAIMS:	18
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT:	1406

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his

     (FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33
     ON 03 SEP 2004
L1         14397 S PROTEIN EXTRACT?
L2          1187 S L1 AND E. COLI CELLS
L3             0 S PROTEIN EXTRACTION WITH ACIDIC PH
L4          1172 S L2 AND ACID
L5            28 S L2 AND ACIDIC PH
L6            28 S L5 AND L4
L7             0 S L6 AND DISRUPT CELLS

=> s l6 and centrifugation
L8            27 L6 AND CENTRIFUGATION

=> s l8 and expanded bed chromatography
L9             1 L8 AND EXPANDED BED CHROMATOGRAPHY

=> d l9 ti abs ibib tot

L9   ANSWER 1 OF 1  USPATFULL on STN
TI     Process for protein extraction
AB     The invention includes a process for extracting a target protein from
       E. coli cells that includes lowering the pH
       of a whole E. coli cell solution to form an acidic solution, disrupting
       the cells to release the protein into the acidic solution, and
       separating the cellular debris from the released protein to obtain a
       protein product enriched in the heterologous target protein. The
       invention also includes addition of a solubility enhancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2004:64493  USPATFULL
TITLE:                    Process for protein extraction
INVENTOR(S):              Gehant, Richard L., South San Francisco, CA, UNITED
                          STATES
PATENT ASSIGNEE(S):       Genentech, Inc., South San Francisco, CA (U.S.
                          corporation)

                               NUMBER         KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 2004049012      A1   20040311
APPLICATION INFO.:        US 2003-655874     A1   20030905  (10)

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2002-408653P    20020906 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN,
                          55402-0903
NUMBER OF CLAIMS:         43
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       8 Drawing Page(s)
LINE COUNT:               752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d his

     (FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)
```

```
      FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33
      ON 03 SEP 2004
L1         14397 S PROTEIN EXTRACT?
L2          1187 S L1 AND E. COLI CELLS
L3             0 S PROTEIN EXTRACTION WITH ACIDIC PH
L4          1172 S L2 AND ACID
L5            28 S L2 AND ACIDIC PH
L6            28 S L5 AND L4
L7             0 S L6 AND DISRUPT CELLS
L8            27 S L6 AND CENTRIFUGATION
L9             1 S L8 AND EXPANDED BED CHROMATOGRAPHY

=> s solubility enhancer
L10          261 SOLUBILITY ENHANCER

=> s l10 and (MgSO4)
L11            2 L10 AND (MGSO4)

=> d l11 ti abs ibib tot

L11  ANSWER 1 OF 2  USPATFULL on STN
TI     Synthesis of epothilones, intermediates thereto and analogues thereof
AB     The present invention provides convergent processes for preparing
       epothilones, desoxyepothilones, and analogues thereof. The present
       invention further provides novel compositions and methods for the
       treatment of cancer and additionally provides methods for the treatment
       of cancer which has developed a multi-drug phenotype.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2002:113071  USPATFULL
TITLE:                    Synthesis of epothilones, intermediates thereto and
                          analogues thereof
INVENTOR(S):              Danishefsky, Samuel J., Englewood, NJ, UNITED STATES
                          Stachel, Shawn J., Perkasie, PA, UNITED STATES
                          Lee, Chul Bom, Princeton, NJ, UNITED STATES
                          Chappell, Mark D., Noblesville, IN, UNITED STATES
                          Wu, Zhicai, New York, NY, UNITED STATES

                               NUMBER         KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 2002058817      A1   20020516
APPLICATION INFO.:        US 2001-796959     A1   20010301  (9)

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2000-185968P    20000301 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     Choate, Hall & Stewart, Exchange Place, 53 State
                          Street, Boston, MA, 02109
NUMBER OF CLAIMS:         5
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       47 Drawing Page(s)
LINE COUNT:               5609
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 2 OF 2  USPATFULL on STN
TI     Synthesis of epothilones, intermediates thereto and analogues thereof
AB     The present invention provides convergent processes for preparing
       epothilones, desoxyepothilones, and analogues thereof. The present
       invention further provides novel compositions and methods for the
       treatment of cancer and additionally provides methods for the treatment
       of cancer which has developed a multi-drug phenotype.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:112551 USPATFULL
TITLE: Synthesis of epothilones, intermediates thereto and analogues thereof
INVENTOR(S): Danishefsky, Samuel J., Englewood, NJ, UNITED STATES
Stachel, Shawn J., Perkasi, PA, UNITED STATES
Lee, Chul Bom, Princeton, NJ, UNITED STATES
Chappell, Mark D., Noblesville, IN, UNITED STATES
Chou, Ting-Chao, Paramus, NJ, UNITED STATES
Wu, Zhicai, New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058286	A1	20020516
APPLICATION INFO.:	US 2001-797027	A1	20010301 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-257072, filed on 24 Feb 1999, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109
NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 47 Drawing Page(s)
LINE COUNT: 6056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33 ON 03 SEP 2004

```
L1         14397 S PROTEIN EXTRACT?
L2          1187 S L1 AND E. COLI CELLS
L3             0 S PROTEIN EXTRACTION WITH ACIDIC PH
L4          1172 S L2 AND ACID
L5            28 S L2 AND ACIDIC PH
L6            28 S L5 AND L4
L7             0 S L6 AND DISRUPT CELLS
L8            27 S L6 AND CENTRIFUGATION
L9             1 S L8 AND EXPANDED BED CHROMATOGRAPHY
L10          261 S SOLUBILITY ENHANCER
L11            2 S L10 AND (MGSO4)

=> s l10 and l8
L12            1 L10 AND L8

=> d l12 ti abs ibib tot

L12  ANSWER 1 OF 1  USPATFULL on STN
TI     Process for protein extraction
AB     The invention includes a process for extracting a target protein from
       E. coli cells that includes lowering the pH
       of a whole E. coli cell solution to form an acidic solution, disrupting
       the cells to release the protein into the acidic solution, and
       separating the cellular debris from the released protein to obtain a
       protein product enriched in the heterologous target protein. The
       invention also includes addition of a solubility
       enhancer.
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:64493 USPATFULL

TITLE: Process for **protein extraction**
INVENTOR(S): Gehant, Richard L., South San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049012	A1	20040311
APPLICATION INFO.:	US 2003-655874	A1	20030905 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-408653P	20020906 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33 ON 03 SEP 2004

```
L1         14397 S PROTEIN EXTRACT?
L2          1187 S L1 AND E. COLI CELLS
L3             0 S PROTEIN EXTRACTION WITH ACIDIC PH
L4          1172 S L2 AND ACID
L5            28 S L2 AND ACIDIC PH
L6            28 S L5 AND L4
L7             0 S L6 AND DISRUPT CELLS
L8            27 S L6 AND CENTRIFUGATION
L9             1 S L8 AND EXPANDED BED CHROMATOGRAPHY
L10          261 S SOLUBILITY ENHANCER
L11            2 S L10 AND (MGSO4)
L12            1 S L10 AND L8
```

=> s l8 and PEI
L13 6 L8 AND PEI

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 6 USPATFULL on STN
TI Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:184572 USPATFULL

TITLE: Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004142455	A1	20040722
APPLICATION INFO.:	US 2003-729039	A1	20031205 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Page(s)
LINE COUNT: 9089
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 2 OF 6 USPATFULL on STN
TI Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:150994 USPATFULL
TITLE: Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004115215	A1	20040617
APPLICATION INFO.:	US 2003-729122	A1	20031205 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Page(s)
LINE COUNT: 16342

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 6 USPATFULL on STN
TI Process for **protein extraction**
AB The invention includes a process for extracting a target protein from **E. coli cells** that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:64493 USPATFULL			
TITLE:	Process for **protein extraction**			
INVENTOR(S):	Gehant, Richard L., South San Francisco, CA, UNITED STATES			
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004049012	A1	20040311	
APPLICATION INFO.:	US 2003-655874	A1	20030905	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2002-408653P		20020906	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903			
NUMBER OF CLAIMS:	43			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	8 Drawing Page(s)			
LINE COUNT:	752			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 6 USPATFULL on STN
TI Soluble recombinant botulinum toxins
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:311862 USPATFULL			
TITLE:	Soluble recombinant botulinum toxins			
INVENTOR(S):	Williams, James A., Madison, WI, UNITED STATES			
PATENT ASSIGNEE(S):	Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA, UNITED STATES, 92612 (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003219457	A1	20031127	
APPLICATION INFO.:	US 2002-271012	A1	20021015	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US			

	5919665
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	40 Drawing Page(s)
LINE COUNT:	16361

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 6 USPATFULL on STN

TI Soluble recombinant botulinum toxin proteins

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:306036 USPATFULL
TITLE:	Soluble recombinant botulinum toxin proteins
INVENTOR(S):	Williams, James A., Madison, WI, UNITED STATES Thalley, Bruce S., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S):	Allergan, Inc., Allergan Botox Limited, Irvine, CA, 92612 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215468	A1	20031120
APPLICATION INFO.:	US 2003-354774	A1	20030130 (10)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	40 Drawing Page(s)
LINE COUNT:	16347

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 6 USPATFULL on STN

TI Compositions and methods for treatment of neoplastic disease

AB The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides, nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that are loaded onto antigen presenting cells to activate both T cells and NKT cells. Cell-based vaccines comprise tumor cells engineered to express a superantigen along with glycolipids products which, when expressed, render the cells capable of eliciting an effective anti-tumor immune response in a mammal into which these cells are introduced. Included among these compositions are tumor cells, hybrid cells of tumor cells and accessory cells, preferably dendritic cells. Also provided are tumoricidal T cells and NKT cells devoid of

inhitory receptors or inhibitory signaling motifs which are hyperresponsive to the the above compositions and lipid-based tumor associated antigens that can be administered for adoptive immunotherapy of cancer and infectious diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:315069 USPATFULL		
TITLE:	Compositions and methods for treatment of neoplastic disease		
INVENTOR(S):	Terman, David S., Pebble Beach, CA, UNITED STATES		

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002177551	A1	20021128
APPLICATION INFO.:	US 2001-870759	A1	20010530 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-208128P	20000531 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	David S. Terman, P.O. Box 987, Pebble Beach, CA, 93953
NUMBER OF CLAIMS:	30
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	3 Drawing Page(s)
LINE COUNT:	17323

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:40:16 ON 03 SEP 2004)

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA' ENTERED AT 09:40:33 ON 03 SEP 2004

L1	14397	S PROTEIN EXTRACT?
L2	1187	S L1 AND E. COLI CELLS
L3	0	S PROTEIN EXTRACTION WITH ACIDIC PH
L4	1172	S L2 AND ACID
L5	28	S L2 AND ACIDIC PH
L6	28	S L5 AND L4
L7	0	S L6 AND DISRUPT CELLS
L8	27	S L6 AND CENTRIFUGATION
L9	1	S L8 AND EXPANDED BED CHROMATOGRAPHY
L10	261	S SOLUBILITY ENHANCER
L11	2	S L10 AND (MGSO4)
L12	1	S L10 AND L8
L13	6	S L8 AND PEI

=> d l8 ti abs ibib 1-10

L8 ANSWER 1 OF 27 USPATFULL on STN

TI Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:184572 USPATFULL
TITLE:	Recombinant botulinum toxins having a soluble C-terminal portion of a heavy chain, an N-terminal portion of a heavy chain and a light chain
INVENTOR(S):	Williams, James A., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S):	Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004142455	A1	20040722
APPLICATION INFO.:	US 2003-729039	A1	20031205 (10)

RELATED APPLN. INFO.:	Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	40 Drawing Page(s)
LINE COUNT:	9089

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 27 USPATFULL on STN

TI Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain

AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:150994 USPATFULL
TITLE:	Recombinant botulinum toxins with a soluble C-terminal portion, an N-terminal portion and a light chain
INVENTOR(S):	Williams, James A., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S):	Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004115215	A1	20040617
APPLICATION INFO.:	US 2003-729122	A1	20031205 (10)

RELATED APPLN. INFO.:	Division of Ser. No. US 2002-271012, filed on 15 Oct 2002, PENDING Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1

NUMBER OF DRAWINGS: 40 Drawing Page(s)
LINE COUNT: 16342
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 27 USPATFULL on STN
TI Process for **protein extraction**
AB The invention includes a process for extracting a target protein from **E. coli cells** that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:64493 USPATFULL
TITLE: Process for **protein extraction**
INVENTOR(S): Gehant, Richard L., South San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004049012	A1	20040311
APPLICATION INFO.:	US 2003-655874	A1	20030905 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-408653P	20020906 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 752
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 27 USPATFULL on STN
TI Soluble recombinant botulinum toxins
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:311862 USPATFULL
TITLE: Soluble recombinant botulinum toxins
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales, Inc., Allergan Botox Limited, Irvine, CA, UNITED STATES, 92612 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219457	A1	20031127
APPLICATION INFO.:	US 2002-271012	A1	20021015 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-704159, filed on 28

Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Page(s)
LINE COUNT: 16361
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 27 USPATFULL on STN
TI Soluble recombinant botulinum toxin proteins
AB The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:306036 USPATFULL
TITLE: Soluble recombinant botulinum toxin proteins
INVENTOR(S): Williams, James A., Madison, WI, UNITED STATES
Thalley, Bruce S., Madison, WI, UNITED STATES
PATENT ASSIGNEE(S): Allergan, Inc., Allergan Botox Limited, Irvine, CA, 92612 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215468	A1	20031120
APPLICATION INFO.:	US 2003-354774	A1	20030130 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1996-704159, filed on 28 Aug 1996, PENDING Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, GRANTED, Pat. No. US 5919665
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STOUT, UXA, BUYAN & MULLINS LLP, 4 VENTURE, SUITE 300, IRVINE, CA, 92618
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Page(s)
LINE COUNT: 16347
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 27 USPATFULL on STN
TI Methods and reagents for decreasing clinical reaction to allergy
AB It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino **acid** within the protein, preferably a hydrophobic residue towards the center of the IgE epitope, to eliminate IgE binding. Additionally or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemically, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino

acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE eitopes and disrupting one or more disulfide bonds of the natural allergen. In certain embodiments, the methods of the present invention allow allergens to be modified while retaining the ability of the protein to activate T-cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity. The Examples provided herein use peanut allergens to illustrate applications of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:288222 USPATFULL

TITLE: Methods and reagents for decreasing clinical reaction to allergy

INVENTOR(S): Caplan, Michael J., Woodbridge, CT, UNITED STATES
Sosin, Howard B., Fairfield, CT, UNITED STATES
Sampson, Hugh, Larchmont, NY, UNITED STATES
Bannon, Gary A., Wentzville, MO, UNITED STATES
Burks, A. Wesley, JR., Little Rock, AR, UNITED STATES
Cockrell, Gael, Cabot, AR, UNITED STATES
Compadre, Cesar M., Little Rock, AR, UNITED STATES
Connaughton, Cathie, Conway, AR, UNITED STATES
Helm, Ricki M., Little Rock, AR, UNITED STATES
King, Nina E., Mason, OH, UNITED STATES
Kopper, Randall A., Conway, AR, UNITED STATES
Maleki, Soheila J., New Orleans, LA, UNITED STATES
Rabjohn, Patrick A., Little Rock, AR, UNITED STATES
Shin, David S., San Diego, CA, UNITED STATES
Stanley, J. Steven, North Little Rock, AR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003202980	A1	20031030
APPLICATION INFO.:	US 2002-100303	A1	20020318 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-494096, filed on 28 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-267719, filed on 11 Mar 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-248674, filed on 11 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-248673, filed on 11 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-241101, filed on 29 Jan 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-240557, filed on 29 Jan 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-141220, filed on 27 Aug 1998, PENDING Continuation-in-part of Ser. No. US 1998-106872, filed on 29 Jun 1998, GRANTED, Pat. No. US 6486311 Continuation-in-part of Ser. No. US 1998-191593, filed on 13 Nov 1998, PENDING Continuation of Ser. No. US 1996-717933, filed on 23 Sep 1996, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-122450P	19990302 (60)
	US 1999-122452P	19990302 (60)
	US 1999-122560P	19990302 (60)
	US 1999-122565P	19990302 (60)
	US 1999-122566P	19990302 (60)
	US 1998-74633P	19980213 (60)
	US 1998-74624P	19980213 (60)
	US 1998-74590P	19980213 (60)
	US 1998-73283P	19980131 (60)
	US 1995-9455P	19951229 (60)

	US 2001-276822P 20010316 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109
NUMBER OF CLAIMS:	40
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	99 Drawing Page(s)
LINE COUNT:	6600

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 27 USPATFULL on STN

TI Method for cleavage of fusion proteins

AB An improved method for recovering recombinantly produced polypeptides is described. The method involves expressing the recombinant polypeptide as a fusion protein with a pro-peptide. The pro-peptide-polypeptide fusion protein can be cleaved and the recombinant polypeptide released under the appropriate conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:238005 USPATFULL
TITLE:	Method for cleavage of fusion proteins
INVENTOR(S):	Van Rooijen, Gijs, Calgary, CANADA Alcantara, Joenel, Calgary, CANADA Moloney, Maurice M., Calgary, CANADA
PATENT ASSIGNEE(S):	SemBioSys Genetics Inc., Calgary, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166162	A1	20030904
APPLICATION INFO.:	US 2002-322746	A1	20021219 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-402488, filed on 16 Feb 2000, PENDING A 371 of International Ser. No. WO 1998-CA398, filed on 23 Apr 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-44254P	19970425 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	BERESKIN AND PARR, SCOTIA PLAZA, 40 KING STREET WEST-SUITE 4000 BOX 401, TORONTO, ON, M5H 3Y2
NUMBER OF CLAIMS:	53
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	19 Drawing Page(s)
LINE COUNT:	1991

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 27 USPATFULL on STN

TI Methods and compositions for production of recombinant peptides

AB This invention entails a method for solubilizing and recovering, in bioactive and isolated form with retained native state configuration, a target peptide from a host organism in which the heterologous polypeptide is present in insoluble form. Broadly this method comprises (i) disrupting the host cell to produce a lysate (ii) recovering lysate precipitate containing the polypeptide (iii) resuspending the lysate precipitate in a denaturant-free, non-buffered solubilization solution to produce a solubilization preparation that comprises both sodium hydroxide between about 8 and about 10 mM and the target peptide between about 1 and about 4 mg peptide per ml solubilization solution, wherein the resultant solubilization preparation has a pH of between about 9 and about 11.2; (iv) recovering supernatant from the solubilization preparation containing non-denatured target peptide. Optionally,

stabilizing compounds and detergents are employed. The invention further comprises isolated insoluble proteins in bioactive form and native state configuration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:237905 USPATFULL
TITLE:	Methods and compositions for production of recombinant peptides
INVENTOR(S):	Gonzalez-Villasenor, Lucia Irene, Baltimore, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003166062	A1	20030904	
APPLICATION INFO.:	US 2002-80919	A1	20020222	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-270839P	20010223	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Thomas M Saunders, Brown Rudnick Berlack Israels LLP, 18th Floor, One Financial Center, Boston, MA, 02111
NUMBER OF CLAIMS:	47
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	1 Drawing Page(s)
LINE COUNT:	2054

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 9 OF 27 USPATFULL on STN

TI Vaccine and antitoxin for treatment and prevention of C. difficile disease

AB The present provides neutralizing antitoxin directed against C. difficile toxins. These antitoxins are produced in avian species using soluble recombinant C. difficile toxin proteins. The avian antitoxins are designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). Solid forms of the antitoxin may comprise an enteric coating. These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin. The invention further provides vaccines capable of protecting a vaccinated recipient from the morbidity and mortality associated with C. difficile infection. These vaccines are useful for administration to humans and other animals at risk of exposure to C. difficile toxins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:234579 USPATFULL
TITLE:	Vaccine and antitoxin for treatment and prevention of C. difficile disease
INVENTOR(S):	Kink, John A., Madison, WI, United States Williams, James A., Lincoln, NE, United States
PATENT ASSIGNEE(S):	Promega Corporation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6613329	B1	20030902	
APPLICATION INFO.:	US 1998-84517		19980526	(9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-422711, filed on 14 Apr 1995, now abandoned Continuation-in-part of Ser. No. US 1995-405496, filed on 16 Mar 1995, now patented, Pat. No. US 5919665 Continuation-in-part of Ser. No. US 1994-329154, filed on 24 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1993-161907, filed			

on 2 Dec 1993, now patented, Pat. No. US 5601823 Continuation-in-part of Ser. No. US 1992-985321, filed on 4 Dec 1992 Continuation-in-part of Ser. No. US 1989-429791, filed on 31 Oct 1989, now patented, Pat. No. US 5196193

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kunz, Gary
ASSISTANT EXAMINER: Turner, Sharon
LEGAL REPRESENTATIVE: Medlen & Carroll, LLP
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 48 Drawing Figure(s); 46 Drawing Page(s)
LINE COUNT: 11913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 10 OF 27 USPATFULL on STN
TI Nucleic acids, proteins, and antibodies
AB The present invention relates to novel proteins. More specifically, isolated nucleic **acid** molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:134527 USPATFULL
TITLE: Nucleic acids, proteins, and antibodies
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092615	A1	20030515
APPLICATION INFO.:	US 2002-115928	A1	20020405 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-764861, filed on 17 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)